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CARDIOVASCULAR DISEASE (including Obesity)
CARDIOVASCULAR DISEASE (including Obesity)—
Clinical Outcomes Studies
PCV1
ZIPRASIDONE VS OLANZAPINE: CONTRASTS IN CHD RISK
Leaderer M, Harrison DJ, Loebel A, Murray S
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: To examine the differences in coronary heart
disease (CHD) risk arising from short-term treatment with the
atypical antipsychotics ziprasidone and olanzapine. METHODS:
Hospitalized schizophrenic adult patients underwent 6 weeks¢
randomized, double-blind treatment with ziprasidone or olanza-
pine, with data collected at baseline and endpoint for fasting
lipids and weekly for blood pressure (BP). A published Fram-
ingham algorithm was used to calculate the percentage CHD risk
that would be incurred over 10 years in patient’s ≥ 30 years (per
algorithm). Baseline-to-endpoint LS mean changes in age-
adjusted risk by sex were compared using ANCOVA (baseline
adjusted). RESULTS: In men, baseline-to-endpoint changes in
total cholesterol (TC) and low-density lipoprotein cholesterol
(LDL-C) were signiﬁcant for olanzapine (n = 56; +22.7 and
+13.9mg/dL, respectively) versus ziprasidone (n = 50; -10.0 and
-6.9mg/dL, respectively) (P < 0.01 for TC, P < 0.05 for LDL-
C). CHD risk in men increased by 0.8% (from a baseline of
4.2%) with olanzapine (n = 55) and decreased by 0.2% (from a
baseline of 4.5%) with ziprasidone (n = 46) (P < 0.05 between
groups). In women, between-group differences were insigniﬁcant
for lipid changes and CHD risk. Neither treatment had signiﬁ-
cant effects on BP. CONCLUSIONS: In short-term treatment 
of men, olanzapine caused signiﬁcant changes in lipid proﬁle
versus ziprasidone, with a consequent signiﬁcant increase in
CHD risk versus ziprasidone. These ﬁndings, coupled with 
those of signiﬁcant weight gain with olanzapine versus ziprasi-
done in comparative studies, warrant investigation in longer-
term trials.
PCV2
COMBINED LIPID GOAL ATTAINMENT IN THE MANAGED
CARE SETTING
Sarawate C1, Bullano MF1, Cziraky MJ1,Willey VJ1, Schrader BJ2,
Charland SL2, Stanek EJ2
1Health Core, Inc, Newark, DE, USA; 2Kos Pharmaceuticals, Inc,
Weston, FL, USA
OBJECTIVES: To evaluate combined low- and high-density
lipoprotein-cholesterol (LDL-C/HDL-C) and triglyceride (TG)
goal attainment and associated therapy over an extended time
period. METHODS: A retrospective cohort analysis using a 1.1
million member southeastern US managed care database.
Patients with a full lipid panel from October 1, 1999–September
39, 2000 (index lab), naive to lipid therapy and with health plan
eligibility 12 months pre and post-index lab were identiﬁed. Pre-
vention status was deﬁned as high-risk primary (age; men > 45
years, women > 55 years; HDL-C < 40mg/dL; hypertension diag-
nosis and therapy), or secondary (pre-index lab vascular event
or revascularization). Lipid goal targets were established using
NCEP ATP-III guidelines. Combined lipid (LDL - C + HDL - C
+ TG) goal attainment was assessed at index and then quarterly
during follow-up. The association between lipid goal achieve-
ment and prescribed therapy was assessed using multinomial
logistic regression. RESULTS: A total of 30,348 patients, with
92,690 lipid panels, were followed for a mean of 27 ± 8 months.
Mean age was 66 ± 12 years, 54% male, and prevention status
was classiﬁed as high-risk primary in 43% and secondary in
57%. Combined lipid goal attainment was observed in 25%,
46%, and 50% of patients at index, 12 and 36 months, respec-
tively. Forty-seven percent of these patients had isolated baseline
high LDL-C. Among the 50% of patients not attaining combined
lipid goals at 36 months, 85% had low HDL-C and/or elevated
TG. Lipid-altering therapy, primarily statin monotherapy (88%),
was prescribed in 30% of patients, after a post-index lag period
of 7 ± 8 months. Prescription of lipid-altering therapy was sig-
niﬁcantly associated with attainment of LDL-C goal (p < 0.05)
but not HDL-C or TG goals. CONCLUSIONS: In this managed
care setting, 50% of high-risk patients did not attain combined
lipid goals, largely due to undertreatment of low HDL-C and/or
elevated TG.
PCV3
USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING
PREDICTORS OF HYPERTENSION TREATMENT
Brown JS1, Menzin J1, Manocchia M2
1Boston Health Economics, Inc, Waltham, MA, USA; 2Blue Cross Blue
Shield of Rhode Island, Providence, RI, USA
OBJECTIVES: The beneﬁts of hypertension therapy for patients
with elevated blood pressure (BP) are well established. The study
objective was to evaluate predictors of drug treatment for
patients with hypertension using a managed-care database that
links health risk appraisal (HRA) data with medical encounter
claims. METHODS: HRA data and physiological measurements
were collected during worksite wellness clinics held at employer
sites in 2002 in the Northeastern US. HRA information included
body mass index (BMI), family history of cardiovascular disease,
tobacco use, self-perceived health status, level of physical activ-
ity, and stages of change, among other measures. Clinical staff
collected BP measurements. Medical encounter and pharmacy
data were summarized for 2001 through 2003 for all clinic par-
ticipants and used to assess medication use and comorbidities.
Cohort selection criteria included elevated BP (diastolic 140
mmHg or higher or systolic 90mmHg or higher), medical insur-
ance eligibility for 2002 and 2003, HRA participation in 2002,
and no BP medication dispensed in 2001. The primary outcome
of interest was the likelihood of initiating antihypertensive drug
therapy in 2002 or 2003. Logistic regression was used to assess
predictors of treatment. RESULTS: The average age of clinic 
participants (n = 506) was 47 years, 59% were male, and 18%
received at least one hypertension medication during the study
period. The likelihood of treatment was positively associated
with BMI (p < 0.01), number of comorbidities (p < 0.001),
hypertension awareness (p < 0.001), self-reported depression or
stress (p = 0.03), and family history of cardiovascular disease (p
= 0.04). Treatment was inversely associated with male gender 
(p = 0.02), but not related to age, self-reported health status, level
of physical activity or tobacco use. CONCLUSION: The likeli-
hood of receiving treatment for hypertension depends on several
factors that rely on surveys, such as the HRA. Combining mul-
tiple data sources can facilitate outcomes research studies in
hypertension.
PCV4
VARIABLE PATIENT COMPLIANCE WITH STATINS AND
ASSOCIATED LIPID CONTROL AMONG CHINESE PATIENTS
WITH HIGH RISK FOR CORONARY HEART DISEASE
Cheng CW1,Woo KS2, Chan JC2,Tomlinson B2, You JH1
1The Chinese University of Hong Kong, Hong Kong, China; 2The
Chinese University of Hong Kong
Coronary heart disease (CHD) is one of the major causes of
death in Hong Kong. Medical non-compliance for patients
receiving statin therapy can cause sub-optimal control of serum
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low-density lipoprotein (LDL) cholesterol and subsequently lead
to cardiovascular events. OBJECTIVE: To examine the associa-
tion of variable patient compliance with statins to the control of
serum LDL. METHODS: A 6-month prospective observational
cohort study was conducted at the outpatient clinics of a public
teaching hospital in Hong Kong. Patients with a 10-year risk for
CHD > 20% or CHD risk equivalents who had been initiated
on statin monotherapy for < 12 months were recruited. The
statin prescription was dispensed to study patients in a bottle
with the Medication Event Monitoring System (MEMS) to
record the date and time the bottle cap was removed and
replaced. Lipid proﬁles were obtained at baseline and two
follow-up visits at month 3 and month 6. RESULTS: A total of
82 patients were recruited and 60.1% were male (mean age = 60
± 12.3 years). Duration of statin treatment prior to study was
6.9 ± 3.2 months. Baseline LDL prior to statin therapy was 3.8
± 0.71mmol/L. Interim ﬁndings showed that LDL was reduced
by 39 ± 14.2% with 84 ± 20% compliance measured as days
with correct dosing at month 3. Signiﬁcant linear relationship
was shown between LDL reduction and days with correct dosing
(R = 0.4848, p = 0.0015), dose count (R = 0.4535, p = 0.002)
but not timing of dose (R = 0.4959, p = 0.09). A 30% reduction
in serum LDL was corresponded to 80% compliance (days with
correct dosing). CONCLUSION: LDL reduction was correlated
with compliance to statin, and 30% LDL reduction appeared to
be achieved at 80% compliance with the prescribed statin
therapy.
PCV5
PREDICTORS OF ADHERENCE WITH CONCOMITANT
ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY
Chapman RH1, Benner JS1, Petrilla AA1,Tierce JC1, Battleman DS2,
Schwartz JS3
1ValueMedics Research, LLC, Arlington,VA, USA; 2Pﬁzer Inc, New
York, NY, USA; 3University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVE: To describe the patterns and predictors of adher-
ence with concomitant antihypertensive (AH) and lipid-lowering
(LL) therapies. METHODS: This retrospective cohort study
evaluated 8406 enrollees in a US managed care plan. Participants
initiated both AH and LL therapies within a 90-day period.
Adherence with AH and LL medications was measured at 3-
month intervals from the start of concomitant therapy for up to
36 months (mean follow-up 12.9 months). Patients were con-
sidered “adherent” with AH and LL therapies if they had ﬁlled
sufﬁcient prescriptions to cover at least 80% of days with both
classes of medications. A multivariate regression model evalu-
ated potential predictors of adherence with concomitant therapy,
including patient demographics, clinical characteristics, and
health service use patterns at baseline. RESULTS: Six months
after treatment initiation, only 36% of patients were adherent
with both AH and LL therapies, 35% did not adhere to either
regimen, and an additional 29% of patients were adherent with
either AH or LL therapy, but not both. These proportions
remained relatively steady over time. In the multivariate model,
age, gender, time since treatment began, and a history of coro-
nary heart disease or congestive heart failure were independently
associated with the likelihood of being adherent. The number of
other medications a patient was taking in the pretreatment year
was strongly and inversely associated with adherence to con-
comitant therapy. In addition, patients were more likely to be
adherent with concomitant therapy if they initiated AH and LL
therapy on or about the same date (within 0–30 days of each
other). CONCLUSIONS: Adherence with concomitant AH and
LL therapy is poor, with only 1 in 3 patients adherent to both
medications at 6 months. Initiating AH and LL therapy together
and keeping the number of other medications to a minimum may
improve adherence with concomitant therapy.
PCV6
ANALYZING RISK OF BLEEDING IN ADMINISTERING LOW
MOLECULAR WEIGHT HEPARINS AND/OR ASPIRIN TO
ORTHOPEDIC PATIENTS
Yin H1,Vogenberg FR2
1University of Illinois, Chicago, IL, USA; 2Aon Consulting Co, Wellesley,
MA, USA
OBJECTIVES: One study documented that physicians tend to
avoid giving prophylaxis to orthopedic patients taking aspirin
due to the concern of increased bleeding, though there is no clear
evidence from the literature. The aim of this study is to deter-
mine whether giving LMWH to patients taking aspirin increases
the hemorrhage risk compared with having only aspirin or
LMWH. This project will also demonstrate the use of the regres-
sion method in outcome research with a large administrative
database. METHODS: Diagnoses and procedures coded in ICD-
9-CM from 15 hospitals across the U.S. that include a mix of
hospital types and geographical locations. In the database, there
were 6847 orthopedic surgery patients who are given LMWH or
aspirin or both: 3680 undergoing hip replacement and 3167
undergoing knee replacement surgery. Logistic regression was
done to assess the bleeding risk. Independent variables included
are anticoagulants taking, procedure (hip/knee), length of stay
(LOS), age, gender, and comorbidities. SAS® for Windows® was
used in the statistical analysis. RESULTS: Combination use of
aspirin and LMWH results higher hemorrhage risk than aspirin
only (p < 0.0001). Combination use of aspirin and LMWH does
not result in different hemorrhage risk than LMWH only 
(p = 0.53). Hip replacement patients have a lower risk than knee
replacement patients. Patients with longer LOS and older
patients have a higher bleeding risk. There was no difference in
bleeding risk by sex. Comorbidities associated with a higher
bleeding risk included cardiovascular diseases, rheumatologic
disease, peptic ulcer, renal disease, malignancy, neurological dis-
orders, drug abuse, and depression. CONCLUSIONS: Based on
our ﬁndings, giving LMWHs to patients taking aspirin results in
more bleeding compared to aspirin alone. However, aspirin does
not inﬂuence the risk of bleeding due to LMWH signiﬁcantly so
patients taking aspirin can receive LMWH. Factors, such as 
age and comorbidities, should be considered before giving
thromboprophylaxis.
PCV7
EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY
CARE IN FRANCE
Van Ganse E1, Moulin P2, Bertrand M3, Souchet T4, Pietri G1,
de Pouvourville G5
1Lyon Sud Hospital, Lyon, France; 2Louis Pradel Hospital, Lyon, France;
3Lille University Hospital, Lambersart, France; 4Merck Sharp &
Dohme—Chibret, Paris, France; 5Collège des Économistes de la
Santé, Paris, France
OBJECTIVE: Cholesterol lowering has been shown to reduce
cardiovascular morbi-mortality. National and international (e.g,
US NCEP) guidelines have deﬁned LDL-C treatment initiation
levels (TIL) and goals for patients with different levels of coro-
nary heart disease (CHD) risk according to the number of CHD
risk factors (CRF) associated to dyslipidemia or to prior CHD.
The objective of this study was to measure the proportions 
of patients above AFSSAPS* TIL [1 CRF > 220mg/dl; 2 CRF >
190mg/dl; 3 CRFs > 160mg/dl; > 3 CRFs and prior CHD >
130mg/dl] and NCEP goal in patients with different CHD risk
level and treated with lipid lowering agents (LLA). METHOD:
